Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients

Zhong, Huahua; Lü, Jun; Jing, Song; Xi, Jianying; Yan, Chong; Song, Jie; Luo, Sushan; Zhao, Chongbo

doi:10.1016/j.jneuroim.2020.577383

Cited by 19 publications

(36 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies made formal or informal comparisons from before treatment to after treatment and described outcomes in cohorts of patients who all received rituximab. Three studies 18,23,26 were multi-centre, and 6 studies [19][20][21][22]24,25 were conducted at a single centre.…”

Section: Methodsmentioning

confidence: 99%

“…These comprised 1 systematic review with meta-analysis 17 and 9 non-randomized studies. [18][19][20][21][22][23][24][25][26] Appendix 1 presents the PRISMA 27 flow chart of the study selection. Additional references of potential interest are provided in Appendix 5.…”

Section: Quantity Of Research Availablementioning

confidence: 99%

“…The non-randomized studies were conducted in Austria, 26 China, 21,24 France, 18 India, 25 Italy, 20 the Republic of Korea, 23 and the US. 19,22…”

Section: Country Of Originmentioning

confidence: 99%

“…All 9 non-randomized studies [18][19][20][21][22][23][24][25][26] included patients with myasthenia gravis who were refractory, steroid-dependent, or who had unacceptable adverse reactions to conventional treatment. The number of relevant patients included in each study ranged between 5 and 56, and the total number of relevant patients included in all non-randomized studies [18][19][20][21][22][23][24][25][26] was 184 (33 of these patients were also included in the systematic review with meta-analysis 17 ). Seven studies 18,20,21,[23][24][25][26] were specific to adult populations, and 1 study 22 was specific to children and adolescents.…”

Section: Patient Populationmentioning

confidence: 99%

See 3 more Smart Citations

Rituximab for the Treatment of Myasthenia Gravis: A 2021 Update

Young¹,

McGill²

2021

cjht

View full text Add to dashboard Cite

Low-quality evidence suggests that treatment with rituximab may be associated with improvements in clinical status, use of concurrent immunomodulatory therapies, quality of life, and various laboratory parameters in patients with myasthenia gravis, compared to before treatment. However, substantial methodological limitations of the included literature limit the use of these findings for informing clinical and policy decisions. Adverse events associated with the use of rituximab were relatively common, occurring in approximately 25% to 45% of patients treated with rituximab. The adverse events experienced by patients were not considered serious by primary study authors. No studies were identified that compared the effectiveness of rituximab to other therapies for the treatment of myasthenia gravis. Summarized studies lacked control groups, meaning that any outcomes observed in study participants should not be attributed to rituximab alone. There is a lack of evidence on the cost-effectiveness of rituximab for the treatment of myasthenia gravis. Additionally, no evidence-based guidelines were identified.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Quantity Of Research Availablementioning

confidence: 99%

“…The non-randomized studies were conducted in Austria, 26 China, 21,24 France, 18 India, 25 Italy, 20 the Republic of Korea, 23 and the US. 19,22…”

Section: Country Of Originmentioning

confidence: 99%

Section: Patient Populationmentioning

confidence: 99%

See 2 more Smart Citations

Rituximab for the Treatment of Myasthenia Gravis: A 2021 Update

Young¹,

McGill²

2021

cjht

View full text Add to dashboard Cite

show abstract

“…In addition to a standard and efficient delivery system for miRNAs, there is a need for mRNA target-specific activity, which can be met by deeply understanding their cellular complexity. A number of clinical trials have been carried out on autoimmune diseases [123,124] and several cancers based on miR-146a [125,126]. A clinical trial was conducted by Pavel and colleagues on former and current smokers suspected of lung cancer that were followed for a year after bronchoscopies.…”

Section: Future Perspectives and Conclusionmentioning

confidence: 99%

Clinico-Pathological Importance of miR-146a in Lung Cancer

et al. 2021

View full text Add to dashboard Cite

Lung cancer is a well-known malignant tumor of the respiratory tract, which has caused a significant level of damage to human health in the 21st century. Micro-RNAs (miRNAs) are tiny, non-coding RNA stem-loop structures with a length of roughly 20–25 nucleotides that function as powerful modulators of mRNA and protein products of a gene. miRNAs may modulate many biological processes involving growth, differentiation, proliferation, and cell death and play a key role in the pathogenesis of various types of malignancies. Several accumulating pieces of evidence have proven that miRNA, especially miR-146a, are crucial modulators of innate immune response sequences. A novel and exciting cancer research field has involved miRNA for the detection and suppression of cancer. However, the actual mechanism which is adopted by these miRNA is still unclear. miRNAs have been used as a cancer-associated biomarker in several studies, suggesting their altered expression in various cancers compared to the normal cells. The amount of expression of miRNA can also be used to determine the stage of the disease, aiding in early detection. In breast, pancreatic, and hepatocellular carcinoma, and gastric cancer, cancer cell proliferation and metastasis has been suppressed by miR-146a. Changes in miR-146a expression levels have biomarker importance and possess a high potential as a therapeutic target in lung cancer. It retards epithelial-mesenchymal transition and promotes the therapeutic action of anticancer agents in lung cancer. Studies have also suggested that miR-146a affects gene expression through different signaling pathways viz. TNF-α, NF-κB and MEK-1/2, and JNK-1/2. Further research is required for understanding the molecular mechanisms of miR-146a in lung cancer. The potential role of miR-146a as a diagnostic marker of lung cancer must also be analyzed. This review summarizes the tumor-suppressing, anti-inflammatory, and antichemoresistive nature of miR-146a in lung cancer.

show abstract

Rituximab in Newly Diagnosed Generalized Myasthenia Gravis

Chuquilin

Barohn

2022

JAMA Neurol

View full text Add to dashboard Cite

Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients

Cited by 19 publications

References 27 publications

Rituximab for the Treatment of Myasthenia Gravis: A 2021 Update

Rituximab for the Treatment of Myasthenia Gravis: A 2021 Update

Clinico-Pathological Importance of miR-146a in Lung Cancer

Rituximab in Newly Diagnosed Generalized Myasthenia Gravis

Contact Info

Product

Resources

About